Details of Disease

General Information of Disease (ID: DISPSQCW)

• Disease Name: Generalized anxiety disorder
• Synonyms: GAD
• Disease Class: 6B00-6B0Z: Anxiety disorder
• Definition: An anxiety disorder characterized by excessive and difficult-to-control worry about a number of life situations. The worry is accompanied by restlessness, fatigue, inability to concentrate, irritability, muscle tension, and/or sleep disturbance and lasts for at least 6 months.
• Disease Hierarchy:
  DISBI2BT: Anxiety disorder
  DISPSQCW: Generalized anxiety disorder
• ICD Code:
  ICD-11: ICD-11: 6B00
  ICD-10: ICD-10: F41.1
  Expand ICD-11: '6B00
  Expand ICD-10: 'F41.1
  Expand ICD-9: 300,300.02,311
• Disease Identifiers:
  MONDO ID: MONDO_0001942
  UMLS CUI: C0270549
  MedGen ID: 452363
  SNOMED CT ID: 21897009

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 7 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
EDG-004	DM9F9J1	Phase 3	NA	[1]
Imagabalin	DMRLVUD	Phase 3	Small molecular drug	[2]
V-419	DM3OJXO	Phase 3	NA	[3]
TGFK08AA	DMNXJ5B	Phase 2	NA	[4]
TGWOOAA	DMI57ZA	Phase 2	NA	[5]
KRL-104	DM56IMO	Phase 1	NA	[6]
Tedatioxetine	DMV5LGJ	Phase 1	Small molecular drug	[7]

This Disease is Treated as An Indication in 2 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Ocinaplon	DMQN3JX	Discontinued in Phase 3	Small molecular drug	[8]
PF-572778	DMZ8HW7	Terminated	NA	[9]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 13 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
NPSR1	TTV1C0Z	Limited	Genetic Variation	[10]
PDE1A	TT73TEJ	Limited	Biomarker	[11]
SLC6A1	TTPRKM0	Limited	Genetic Variation	[12]
SLC6A12	TTQBMPI	Limited	Biomarker	[12]
SMC2	TTS8D17	Limited	Biomarker	[13]
STK32B	TT4D2GZ	Limited	Genetic Variation	[14]
GAD1	TTKGEP3	Strong	Genetic Variation	[15]
GAD2	TT7UY6K	Strong	Biomarker	[16]
HTR2A	TTJQOD7	Strong	Genetic Variation	[17]
SLC30A8	TTXIGT7	Strong	Genetic Variation	[18]
SLC6A4	TT3ROYC	Strong	Genetic Variation	[19]
CRHR1	TT7EFHR	Definitive	Genetic Variation	[11]
HTR1A	TTSQIFT	Definitive	Biomarker	[20]

This Disease Is Related to 1 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLC30A10	DTYBI73	Strong	Genetic Variation	[18]

This Disease Is Related to 1 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
SCLY	DEH4TD6	Strong	Biomarker	[21]

This Disease Is Related to 19 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ASPRV1	OT8WVIBW	Limited	Biomarker	[22]
CACYBP	OTJMZD2T	Limited	Genetic Variation	[23]
COBL	OTTB4VFQ	Limited	Genetic Variation	[24]
DYNLL2	OTLIT58K	Limited	Biomarker	[25]
HGS	OTCYYCAC	Limited	Biomarker	[26]
KANK2	OT3SZIWM	Limited	Genetic Variation	[23]
MMD	OTB5I4OC	Limited	Biomarker	[27]
NDUFS4	OTJKUYEE	Limited	Genetic Variation	[28]
PHOX2B	OT3SFR2O	Limited	Biomarker	[29]
RBM14	OTO9GMBD	Limited	Genetic Variation	[23]
SRSF5	OTC5WP98	Limited	Biomarker	[26]
TLE5	OTEH0BFG	Limited	Biomarker	[30]
TP53INP1	OT2363Z9	Limited	Genetic Variation	[23]
TSACC	OT3QW6PH	Limited	Genetic Variation	[23]
ATF7IP	OTU6ZA7F	Strong	Biomarker	[31]
CSTA	OT1K68KE	Strong	Biomarker	[32]
TMED9	OTYGAQS0	Strong	Biomarker	[33]
OSR1	OTB19LEQ	Definitive	Biomarker	[34]
TAL1	OTX4K6QZ	Definitive	Biomarker	[35]

References

• [1] ClinicalTrials.gov (NCT02305797) EDG004 Treatment of Adult Patients With Generalized Anxiety Disorder (GAD). U.S. National Institutes of Health.
• [2] Methodology for rapid measures of glutamate release in rat brain slices using ceramic-based microelectrode arrays: basic characterization and drug pharmacology. Brain Res. 2011 Jul 15;1401:1-9.
• [3] ClinicalTrials.gov (NCT01337167) Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13 and RotaTeq (V419-005 AM4). U.S. National Institutes of Health.
• [4] Clinical pipeline report, company report or official report of Fabre-Kramer Pharmaceuticals.
• [5] Clinical pipeline report, company report or official report of Fabre-Kramer Pharmaceuticals.
• [6] Pharmaceutical Research Companies Are Developing More Than 300 Medicines to Treat Mental Illnesses. Pharmaceutical Research and Manufacturers of America report.2010.
• [7] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023694)
• [8] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4277).
• [9] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025528)
• [10] Association of NPSR1 rs324981 polymorphism and treatment response to antidepressants in Chinese Han population with generalized anxiety disorder.Biochem Biophys Res Commun. 2018 Sep 26;504(1):137-142. doi: 10.1016/j.bbrc.2018.08.145. Epub 2018 Sep 3.
• [11] Pharmacogenetic investigation of response to duloxetine treatment in generalized anxiety disorder.Pharmacogenomics J. 2013 Jun;13(3):280-5. doi: 10.1038/tpj.2011.62. Epub 2012 Jan 17.
• [12] Kava for generalised anxiety disorder: A 16-week double-blind, randomised, placebo-controlled study.Aust N Z J Psychiatry. 2020 Mar;54(3):288-297. doi: 10.1177/0004867419891246. Epub 2019 Dec 8.
• [13] Common mental disorder including psychotic experiences: Trailblazing a new recovery pathway within the Improving Access to Psychological Therapies programme in England.Early Interv Psychiatry. 2018 Jun;12(3):497-504. doi: 10.1111/eip.12434. Epub 2017 May 16.
• [14] Changes in methylation within the STK32B promoter are associated with an increased risk for generalized anxiety disorder in adolescents.J Psychiatr Res. 2018 Jul;102:44-51. doi: 10.1016/j.jpsychires.2018.03.008. Epub 2018 Mar 26.
• [15] Psychometric properties of worry and anxiety measures in a sample of african american and caucasian older adults.Aging Ment Health. 2020 Feb;24(2):315-321. doi: 10.1080/13607863.2018.1544217. Epub 2019 Feb 27.
• [16] The Psychometric Properties and Clinical Utility of the Korean Version of GAD-7 and GAD-2.Front Psychiatry. 2019 Mar 18;10:127. doi: 10.3389/fpsyt.2019.00127. eCollection 2019.
• [17] Serotonin receptor 2A (HTR2A) gene polymorphism predicts treatment response to venlafaxine XR in generalized anxiety disorder.Pharmacogenomics J. 2013 Feb;13(1):21-6. doi: 10.1038/tpj.2011.47. Epub 2011 Oct 18.
• [18] Characteristics of slow progression to diabetes in multiple islet autoantibody-positive individuals from five longitudinal cohorts: the SNAIL study.Diabetologia. 2018 Jun;61(6):1484-1490. doi: 10.1007/s00125-018-4591-5. Epub 2018 Mar 12.
• [19] A pilot study on predictors of brainstem raphe abnormality in patients with major depressive disorder.J Affect Disord. 2017 Feb;209:66-70. doi: 10.1016/j.jad.2016.11.034. Epub 2016 Nov 22.
• [20] Role of tandospirone, a 5-HT1A receptor partial agonist, in the treatment of central nervous system disorders and the underlying mechanisms.Oncotarget. 2017 Oct 27;8(60):102705-102720. doi: 10.18632/oncotarget.22170. eCollection 2017 Nov 24.
• [21] The Utility of the Hopkins Symptom Checklist as a Trans-Diagnostic Screening Instrument for Common Mental Disorders Among Persons Seeking HIV Testing.AIDS Behav. 2020 Feb;24(2):629-636. doi: 10.1007/s10461-019-02524-6.
• [22] Implementing electronic substance use disorder and depression and anxiety screening and behavioral interventions in primary care clinics serving people with HIV: Protocol for the Promoting Access to Care Engagement (PACE) trial.Contemp Clin Trials. 2019 Sep;84:105833. doi: 10.1016/j.cct.2019.105833. Epub 2019 Aug 22.
• [23] Is the effect of work-related psychosocial exposure on depressive and anxiety disorders short-term, lagged or cumulative?.Int Arch Occup Environ Health. 2020 Jan;93(1):87-104. doi: 10.1007/s00420-019-01466-9. Epub 2019 Aug 3.
• [24] Characteristics of rapid vs slow progression to type 1 diabetes in multiple islet autoantibody-positive children.Diabetologia. 2013 Jul;56(7):1615-22. doi: 10.1007/s00125-013-2896-y. Epub 2013 Mar 29.
• [25] An association analysis of murine anxiety genes in humans implicates novel candidate genes for anxiety disorders.Biol Psychiatry. 2008 Oct 15;64(8):672-680. doi: 10.1016/j.biopsych.2008.06.002. Epub 2008 Jul 17.
• [26] Factor structure, reliability, and validity of the Japanese version of the Hoarding Rating Scale-Self-Report (HRS-SR-J).Neuropsychiatr Dis Treat. 2017 May 9;13:1235-1243. doi: 10.2147/NDT.S133471. eCollection 2017.
• [27] Evaluating quality of life in epilepsy: The role of screening for adverse drug effects, depression, and anxiety.Epilepsy Behav. 2017 Oct;75:18-24. doi: 10.1016/j.yebeh.2017.07.016. Epub 2017 Aug 15.
• [28] Prediction of type 1 diabetes among siblings of affected children and in the general population.Diabetologia. 2007 Nov;50(11):2272-5. doi: 10.1007/s00125-007-0799-5. Epub 2007 Sep 4.
• [29] Descriptive Epidemiology of Generalized Anxiety Disorder in Canada.Can J Psychiatry. 2017 Jan;62(1):24-29. doi: 10.1177/0706743716645304. Epub 2016 Jul 10.
• [30] Apathy in people with epilepsy and its clinical significance: A case-control study.Seizure. 2017 Oct;51:80-86. doi: 10.1016/j.seizure.2017.08.003. Epub 2017 Aug 8.
• [31] Therapeutic efficacy and safety of chamomile for state anxiety, generalized anxiety disorder, insomnia, and sleep quality: A systematic review and meta-analysis of randomized trials and quasi-randomized trials.Phytother Res. 2019 Jun;33(6):1604-1615. doi: 10.1002/ptr.6349. Epub 2019 Apr 21.
• [32] Real-World Evidence from the Integrative Medicine Primary Care Trial (IMPACT): Assessing Patient-Reported Outcomes at Baseline and 12-Month Follow-Up.Evid Based Complement Alternat Med. 2019 Jun 26;2019:8595409. doi: 10.1155/2019/8595409. eCollection 2019.
• [33] The Effect of Insomnia on Cortical Excitability in Patients With Generalized Anxiety Disorder.Front Psychiatry. 2019 Jan 10;9:755. doi: 10.3389/fpsyt.2018.00755. eCollection 2018.
• [34] External validation of a bifactor model of oppositional defiant disorder.Mol Psychiatry. 2021 Feb;26(2):682-693. doi: 10.1038/s41380-018-0294-z. Epub 2018 Dec 11.
• [35] Parental Stress of Preschool Children With Generalized Anxiety or Oppositional Defiant Disorder.Front Pediatr. 2019 Oct 17;7:415. doi: 10.3389/fped.2019.00415. eCollection 2019.